The effect and mechanism of liraglutide on the biological functions of BMSCs in diabetic patients.

IF 2.9 3区医学 Q1 DENTISTRY, ORAL SURGERY & MEDICINE Oral diseases Pub Date : 2024-11-01 Epub Date: 2024-03-19 DOI:10.1111/odi.14931

Yao Wang, Yujie Sun, Bo Yang, Jun Li, Chao Liang

{"title":"The effect and mechanism of liraglutide on the biological functions of BMSCs in diabetic patients.","authors":"Yao Wang, Yujie Sun, Bo Yang, Jun Li, Chao Liang","doi":"10.1111/odi.14931","DOIUrl":null,"url":null,"abstract":"Objectives: To investigate the effect of liraglutide on osteogenesis in human alveolar bone marrow mesenchymal stem cells (BMSCs) and the influence of liraglutide on implant-bone integration in rats with T2DM.Subjects and methods: Extracting BMSCs from the alveoli of diabetic patients treated with insulin. BMSCs were treated with different concentrations of liraglutide. Osteogenesis and the underlying mechanism were investigated via ALP detection, ALP staining, Alizarin Red S staining, Western blotting, and RT-PCR. Liraglutide was given to Wistar and GK rats after implantation, and new bone formation around the implants was analyzed via micro-CT. Implant-bone integration in rats was investigated via toluidine blue staining.Results: Liraglutide enhanced osteogenesis in BMSCs via the BMP2/Smad/Runx2 signaling pathway. The optimal concentration of liraglutide that promoted osteogenesis was 10-8 mol/L. At concentrations higher than 10-7 mol/L, liraglutide had a negative effect on BMSCs. At a concentration of 10-8 mol/L liraglutide, BMSCs and diabetes mellitus-bone marrow stromal cells (DM-BMSCs) showed optimal osteogenesis. Liraglutide promoted implant-bone integration and new bone formation in Wistar and GK rats.Conclusions: Liraglutide not only promotes osteogenesis of BMSCs in normoglycemic individuals but also enhances osteogenesis of BMSCs in diabetic patients treated with insulin and enhances osseointegration in rats.","PeriodicalId":19615,"journal":{"name":"Oral diseases","volume":" ","pages":"5160-5174"},"PeriodicalIF":2.9000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oral diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/odi.14931","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/19 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"DENTISTRY, ORAL SURGERY & MEDICINE","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: To investigate the effect of liraglutide on osteogenesis in human alveolar bone marrow mesenchymal stem cells (BMSCs) and the influence of liraglutide on implant-bone integration in rats with T2DM.

Subjects and methods: Extracting BMSCs from the alveoli of diabetic patients treated with insulin. BMSCs were treated with different concentrations of liraglutide. Osteogenesis and the underlying mechanism were investigated via ALP detection, ALP staining, Alizarin Red S staining, Western blotting, and RT-PCR. Liraglutide was given to Wistar and GK rats after implantation, and new bone formation around the implants was analyzed via micro-CT. Implant-bone integration in rats was investigated via toluidine blue staining.

Results: Liraglutide enhanced osteogenesis in BMSCs via the BMP2/Smad/Runx2 signaling pathway. The optimal concentration of liraglutide that promoted osteogenesis was 10^-8 mol/L. At concentrations higher than 10^-7 mol/L, liraglutide had a negative effect on BMSCs. At a concentration of 10^-8 mol/L liraglutide, BMSCs and diabetes mellitus-bone marrow stromal cells (DM-BMSCs) showed optimal osteogenesis. Liraglutide promoted implant-bone integration and new bone formation in Wistar and GK rats.

Conclusions: Liraglutide not only promotes osteogenesis of BMSCs in normoglycemic individuals but also enhances osteogenesis of BMSCs in diabetic patients treated with insulin and enhances osseointegration in rats.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

利拉鲁肽对糖尿病患者 BMSCs 生物功能的影响和机制。

研究目的研究利拉鲁肽对人肺泡骨髓间充质干细胞（BMSCs）成骨的影响，以及利拉鲁肽对T2DM大鼠植入物-骨整合的影响：从接受胰岛素治疗的糖尿病患者肺泡中提取骨髓间充质干细胞。用不同浓度的利拉鲁肽处理 BMSCs。通过ALP检测、ALP染色、茜素红S染色、Western印迹和RT-PCR研究骨生成及其机制。给 Wistar 大鼠和 GK 大鼠植入利拉鲁肽后，通过显微 CT 分析植入物周围新骨的形成。通过甲苯胺蓝染色法研究大鼠植入物与骨的整合情况：结果：利拉鲁肽通过BMP2/Smad/Runx2信号通路增强了BMSCs的成骨作用。利拉鲁肽促进成骨的最佳浓度为 10-8 mol/L。当浓度高于 10-7 mol/L 时，利拉鲁肽会对 BMSCs 产生负面影响。当利拉鲁肽的浓度为10-8 mol/L时，BMSCs和糖尿病骨髓基质细胞（DM-BMSCs）的成骨效果最佳。利拉鲁肽促进了 Wistar 大鼠和 GK 大鼠的植入骨整合和新骨形成：结论：利拉鲁肽不仅能促进血糖正常者骨髓基质细胞的成骨，还能增强接受胰岛素治疗的糖尿病患者骨髓基质细胞的成骨，并增强大鼠的骨整合。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Oral diseases 医学-牙科与口腔外科

CiteScore

7.60

自引率

5.30%

发文量

325

审稿时长

4-8 weeks

期刊介绍： Oral Diseases is a multidisciplinary and international journal with a focus on head and neck disorders, edited by leaders in the field, Professor Giovanni Lodi (Editor-in-Chief, Milan, Italy), Professor Stefano Petti (Deputy Editor, Rome, Italy) and Associate Professor Gulshan Sunavala-Dossabhoy (Deputy Editor, Shreveport, LA, USA). The journal is pre-eminent in oral medicine. Oral Diseases specifically strives to link often-isolated areas of dentistry and medicine through broad-based scholarship that includes well-designed and controlled clinical research, analytical epidemiology, and the translation of basic science in pre-clinical studies. The journal typically publishes articles relevant to many related medical specialties including especially dermatology, gastroenterology, hematology, immunology, infectious diseases, neuropsychiatry, oncology and otolaryngology. The essential requirement is that all submitted research is hypothesis-driven, with significant positive and negative results both welcomed. Equal publication emphasis is placed on etiology, pathogenesis, diagnosis, prevention and treatment.